These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 4175192)

  • 1. Anti-tumour effect of activated lymphocytes.
    Svet-Moldavsky GJ; Kadaghidze ZG
    Lancet; 1968 Sep; 2(7568):641-2. PubMed ID: 4175192
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-tumour effect of activated lymphocytes.
    Svetemoldavsky GJ; Kadaghidze ZG
    Lancet; 1968 Sep; 2(7568):641. PubMed ID: 4175191
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of advanced ageing on the ability of mice to cause tumour regression in response to immunotherapy.
    Dunn PL; North RJ
    Immunology; 1991 Oct; 74(2):355-9. PubMed ID: 1748485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the effectiveness of regional interleukin-2 dependent adoptive immunocytotherapy of mice with transplanted rhabdomyosarcoma].
    Semenova-Kobzar' RA; Iudin VM; Kushko LIa; Iakhimovich LV; Berezhnaia NM
    Eksp Onkol; 1990; 12(3):50-2. PubMed ID: 2344825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Vaccinia virus as an adjuvant in inducing specific anti-tumour immunity to transplantable mouse fibrosarcoma. II. Rejection of tumour graft 'in vivo' humoral and lymphocytotoxicity 'in vitro'.
    Bendre AR; Gangal SG
    Indian J Cancer; 1978 Dec; 15(4):9-16. PubMed ID: 757692
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-tumour efficacy of IL-1 and IL-2.
    Bubeník J; Indrová M; Holán V
    Folia Biol (Praha); 1988; 34(1):42-7. PubMed ID: 3260564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Vaccinia virus as an adjuvant in inducing specific anti-tumour immunity to transplantable mouse fibrosarcoma. I. Adaptation of the virus to mouse tumour cells as a pre-requisit for adjuvanticity.
    Bendre AR; Gangal SG
    Indian J Cancer; 1978 Dec; 15(4):1-8. PubMed ID: 757683
    [No Abstract]   [Full Text] [Related]  

  • 8. [Methotrexate induction of the lethal effect of lymphocytes on target-cells].
    Kadagidze ZG; Sura SN
    Dokl Akad Nauk SSSR; 1968 Mar; 179(3):715-6. PubMed ID: 5747822
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship of radioresistance and immunoresistance in an experimental tumour.
    Koldovský P; Adamcová B; Bubeník J
    Folia Biol (Praha); 1965; 11(5):393-5. PubMed ID: 5845264
    [No Abstract]   [Full Text] [Related]  

  • 10. [Enhancement of tumor-specific killer T cell activities by high-dose methotrexate].
    Chigira M
    Nihon Seikeigeka Gakkai Zasshi; 1983 May; 57(5):533-8. PubMed ID: 6224870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy by using cyclophosphamide and tumor-sensitized lymphocytes: a possible mechanism of action.
    Evans R
    J Immunol; 1983 Jun; 130(6):2511-3. PubMed ID: 6133894
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cytotoxic activity in mouse tumors by lymphocytes with anti-streptococcal specific antibodies].
    Fujioka T; Tanji S; Koike H; Kumagai K; Aoki H; Kubo T; Ohhori T
    Nihon Gan Chiryo Gakkai Shi; 1988 Jun; 23(6):1243-7. PubMed ID: 3068321
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antitumor activity of the serum and lymphocytes of C57BL mice in chemical carcinogenesis].
    Umanskiĭ IuA; Kushko LIa; Semenova-Kobzar' RA
    Vopr Onkol; 1980; 26(2):42-6. PubMed ID: 7361493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An approach for the generation of effector lymphocytes from tumor-bearing hosts for the adoptive immunotherapy of established tumors.
    Shu SY; Chou T
    Prog Clin Biol Res; 1987; 244():27-37. PubMed ID: 3498953
    [No Abstract]   [Full Text] [Related]  

  • 15. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of hyperthermia and methotrexate in the treatment of transplanted Walker sarcoma.
    Kosmidis PA; Uzunoglou N; Elemenoglou J; Kottaridis S
    Chemioterapia; 1988 Jun; 7(3):184-8. PubMed ID: 3168074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth.
    Forni G; Musso T; Santoni A; Giovarelli M
    Prog Clin Biol Res; 1987; 244():105-14. PubMed ID: 2958866
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased growth of tumor isotransplants after immunosuppression of the recipient mice by methotrexate or 5-fluoro-2'-deoxyuridine.
    Reiner J; Southam CM
    J Natl Cancer Inst; 1967 May; 38(5):753-9. PubMed ID: 4225921
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanism of tumour regression by tumour cell extract.
    Batra BK; Raveendran P; Menon IR
    Indian J Med Res; 1975 Jan; 63(1):31-5. PubMed ID: 174999
    [No Abstract]   [Full Text] [Related]  

  • 20. Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour.
    Digiacomo A; North RJ
    Immunology; 1987 Mar; 60(3):367-73. PubMed ID: 2952585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.